Covalent	O
labeling	O
of	O
rat	B-cell_type
thymocyte	I-cell_type
and	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

Lymphoid	B-cell_type
cells	I-cell_type
contain	O
specific	O
receptors	B-protein
for	O
glucocorticoids	O
.	O

We	O
have	O
used	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
to	O
label	O
covalently	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
neoplastic	B-cell_type
cells	I-cell_type
obtained	O
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
.	O

The	O
covalently	O
labeled	O
glucocorticoid	B-protein
receptors	I-protein
were	O
identified	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	O
the	O
presence	O
of	O
0.1	O
%	O
sodium	O
dodecyl	O
sulfate	O
)	O
.	O

In	O
cytosolic	O
fractions	O
prepared	O
from	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
,	O
[	O
3H	O
]	O
-dexamethasone-21-mesylate	O
labels	O
a	O
protein	O
(	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
)	O
which	O
was	O
identified	O
as	O
the	O
glucocorticoid	B-protein
receptor	I-protein
by	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
labeling	O
of	O
this	O
moiety	O
is	O
inhibited	O
by	O
treatment	O
with	O
a	O
100-fold	O
molar	O
excess	O
of	O
glucocorticoids	O
,	O
such	O
as	O
dexamethasone	O
and	O
triamcinolone	O
acetonide	O
;	O
and	O
(	O
b	O
)	O
the	O
covalently	O
labeled	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
protein	O
is	O
activated	O
(	O
by	O
heating	O
at	O
20	O
degrees	O
for	O
30	O
min	O
)	O
to	O
a	O
form	O
that	O
binds	O
to	O
DNA-cellulose	O
.	O

When	O
intact	B-cell_type
thymocytes	I-cell_type
are	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
is	O
also	O
labeled	O
covalently	O
.	O

Approximately	O
35	O
%	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
labeled	O
covalently	O
when	O
intact	O
thymocytes	B-cell_type
are	O
treated	O
with	O
100	O
nM	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
for	O
30	O
min	O
at	O
4	O
degrees	O
.	O

Neoplastic	B-cell_type
cells	I-cell_type
from	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
were	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
.	O

In	O
all	O
samples	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
was	O
labeled	O
covalently	O
;	O
labeling	O
was	O
inhibited	O
by	O
excess	O
glucocorticoid	O
.	O

Smaller	B-protein
moieties	I-protein
were	O
also	O
identified	O
by	O
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	B-protein
fragments	I-protein
of	O
the	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
receptor	O
.	O

Thus	O
,	O
in	O
rat	B-cell_type
and	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
can	O
be	O
used	O
to	O
label	O
covalently	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
43	NULL
,	NULL
5273-5277	NULL
,	NULL
November	NULL
1983	NULL
]	NULL
Covalent	NULL
Labeling	NULL
of	NULL
Rat	NULL
Thymocyte	NULL
and	NULL
Human	NULL
Lymphoid	NULL
Glucocorticoid	NULL
Receptor	NULL
'	NULL
Carol	NULL
M.	NULL
Foster	NULL
,	NULL
``	NULL
Howard	NULL
J.	NULL
Eisen	NULL
,	NULL
and	NULL
Clara	NULL
D.	NULL
Bloomfield	NULL
Laboratory	NULL
of	NULL
Developmental	NULL
Pharmacology	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Child	NULL
Health	NULL
and	NULL
Human	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20205	NULL
[	NULL
C.	NULL
M.	NULL
F.	NULL
,	NULL
H.	NULL
J.	NULL
E.	NULL
]	NULL
,	NULL
and	NULL
Section	NULL
of	NULL
Medical	NULL
Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Minnesota	NULL
,	NULL
Minneapolis	NULL
,	NULL
Minnesota	NULL
55455	NULL
[	NULL
C.	NULL
D	NULL
.	NULL

B	NULL
.	NULL
]	NULL

ABSTRACT	NULL
Lymphoid	NULL
cells	NULL
contain	NULL
specific	NULL
receptors	NULL
for	NULL
glucocorticoids	NULL
.	NULL

We	NULL
have	NULL
used	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-mesylate	NULL
to	NULL
label	NULL
covalently	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
and	NULL
in	NULL
neoplastic	NULL
cells	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
and	NULL
malignant	NULL
lymphoma	NULL
.	NULL

The	NULL
covalently	NULL
labeled	NULL
glucocorticoid	NULL
receptors	NULL
were	NULL
identified	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
)	NULL
.	NULL

In	NULL
cytosolic	NULL
fractions	NULL
prepared	NULL
from	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-mesylate	NULL
labels	NULL
a	NULL
protein	NULL
(	NULL
M	NULL
,	NULL
=95,000	NULL
)	NULL
which	NULL
was	NULL
identified	NULL
as	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
by	NULL
the	NULL
following	NULL
criteria	NULL
:	NULL
(	NULL
a	NULL
)	NULL
labeling	NULL
of	NULL
this	NULL
moiety	NULL
is	NULL
inhibited	NULL
by	NULL
treatment	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
glucocorticoids	NULL
,	NULL
such	NULL
as	NULL
dexamethasone	NULL
and	NULL
triamcinolone	NULL
acetonide	NULL
;	NULL
and	NULL
(	NULL
b	NULL
)	NULL
the	NULL
covalently	NULL
labeled	NULL
M	NULL
,	NULL
295,000	NULL
protein	NULL
is	NULL
activated	NULL
(	NULL
by	NULL
heating	NULL
at	NULL
20°	NULL
for	NULL
30	NULL
min	NULL
)	NULL
to	NULL
a	NULL
form	NULL
that	NULL
binds	NULL
to	NULL
DNA-cellulose	NULL
.	NULL

When	NULL
intact	NULL
thymocytes	NULL
are	NULL
treated	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-mesylate	NULL
,	NULL
an	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
is	NULL
also	NULL
labeled	NULL
covalently	NULL
.	NULL

Approximately	NULL
35	NULL
%	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
can	NULL
be	NULL
labeled	NULL
covalently	NULL
when	NULL
intact	NULL
thymocytes	NULL
are	NULL
treated	NULL
with	NULL
100	NULL
nm	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-mesylate	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°	NULL
.	NULL

Neoplastic	NULL
cells	NULL
from	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
and	NULL
malignant	NULL
lymphoma	NULL
were	NULL
treated	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-me-sylate	NULL
.	NULL

In	NULL
all	NULL
samples	NULL
,	NULL
an	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
was	NULL
labeled	NULL
cova-lently	NULL
;	NULL
labeling	NULL
was	NULL
inhibited	NULL
by	NULL
excess	NULL
glucocorticoid	NULL
.	NULL

Smaller	NULL
moieties	NULL
were	NULL
also	NULL
identified	NULL
by	NULL
competition	NULL
experiments	NULL
;	NULL
these	NULL
may	NULL
represent	NULL
proteolytic	NULL
fragments	NULL
of	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
receptor	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
rat	NULL
and	NULL
human	NULL
lymphoid	NULL
cells	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone-21-mesylate	NULL
can	NULL
be	NULL
used	NULL
to	NULL
label	NULL
covalently	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

INTRODUCTION	NULL
Glucocorticoids	NULL
are	NULL
used	NULL
widely	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
lymphoid	NULL
cancers	NULL
,	NULL
such	NULL
as	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
and	NULL
lymphocytic	NULL
lymphoma	NULL
.	NULL

The	NULL
therapeutic	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
may	NULL
involve	NULL
specific	NULL
glucocorticoid	NULL
receptors	NULL
found	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
10	NULL
,	NULL
16	NULL
)	NULL
.	NULL

However	NULL
,	NULL
not	NULL
all	NULL
lymphoid	NULL
cancers	NULL
are	NULL
responsive	NULL
to	NULL
glucocorticoids	NULL
(	NULL
3	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Defects	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
different	NULL
malignant	NULL
cell	NULL
types	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
variation	NULL
in	NULL
sensitivity	NULL
of	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
to	NULL
glucocorticoid	NULL
ther-apy	NULL
.	NULL

Such	NULL
defects	NULL
have	NULL
been	NULL
described	NULL
in	NULL
murine	NULL
and	NULL
human	NULL
lymphoma	NULL
and	NULL
leukemia	NULL
cell	NULL
lines	NULL
(	NULL
14	NULL
,	NULL
16	NULL
,	NULL
22	NULL
)	NULL
and	NULL
have	NULL
been	NULL
suggested	NULL
recently	NULL
in	NULL
human	NULL
leukemia	NULL
(	NULL
1	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Until	NULL
recently	NULL
,	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
lymphoid	NULL
cells	NULL
have	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
NIH	NULL
Grant	NULL
CA	NULL
26273	NULL
,	NULL
American	NULL
Cancer	NULL
Society	NULL
Grant	NULL
CH-167	NULL
,	NULL
and	NULL
the	NULL
Coleman	NULL
Leukemia	NULL
Research	NULL
Fund	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
6C-101	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

20205	NULL
.	NULL

Received	NULL
April	NULL
15	NULL
,	NULL
1983	NULL
;	NULL
accepted	NULL
August	NULL
5	NULL
,	NULL
1983	NULL
.	NULL

NOVEMBER	NULL
1983	NULL
only	NULL
been	NULL
detectable	NULL
by	NULL
use	NULL
of	NULL
radiolabeled	NULL
steroids	NULL
(	NULL
such	NULL
as	NULL
dexamethasone	NULL
)	NULL
,	NULL
which	NULL
form	NULL
noncovalent	NULL
steroid	NULL
:	NULL
receptor	NULL
complexes	NULL
that	NULL
dissociate	NULL
readily	NULL
.	NULL

In	NULL
order	NULL
to	NULL
study	NULL
receptor	NULL
differences	NULL
in	NULL
leukemic	NULL
cells	NULL
,	NULL
it	NULL
would	NULL
be	NULL
beneficial	NULL
to	NULL
use	NULL
a	NULL
receptor	NULL
label	NULL
which	NULL
remains	NULL
stable	NULL
under	NULL
analytical	NULL
conditions	NULL
.	NULL

Affinity	NULL
labeling	NULL
has	NULL
been	NULL
used	NULL
to	NULL
label	NULL
covalently	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
rat	NULL
liver	NULL
(	NULL
7	NULL
)	NULL
,	NULL
rat	NULL
HTC®	NULL
cells	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
,	NULL
and	NULL
mouse	NULL
lymphoma	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
used	NULL
[	NULL
°HJDM	NULL
to	NULL
label	NULL
covalently	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
rat	NULL
thymocytes	NULL
.	NULL

These	NULL
techniques	NULL
were	NULL
then	NULL
applied	NULL
to	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
lymphoma	NULL
and	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Chemicals	NULL
.	NULL

°H	NULL
]	NULL
JTA	NULL
(	NULL
37	NULL
Ci/mmol	NULL
)	NULL
and	NULL
[	NULL
°HJDM	NULL
(	NULL
46	NULL
Ci/mmol	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL

TA	NULL
dexametha-sone	NULL
,	NULL
sodium	NULL
molybdate	NULL
,	NULL
and	NULL
3-	NULL
{	NULL
[	NULL
tris	NULL
(	NULL
hydroxymethyl	NULL
)	NULL
methylJlaminopro-pane	NULL
sulfonic	NULL
acid	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL

Ready-Solv	NULL
MP	NULL
scintillation	NULL
fluid	NULL
was	NULL
purchased	NULL
from	NULL
Beckman	NULL
instruments	NULL
,	NULL
Inc.	NULL
,	NULL
Berkeley	NULL
,	NULL
Calif.	NULL
Hydroxylapatite	NULL
was	NULL
purchased	NULL
from	NULL
LKB	NULL
Instruments	NULL
,	NULL
Inc.	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL

Analytically	NULL
pure	NULL
DM	NULL
was	NULL
obtained	NULL
as	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
S.	NULL
Simons	NULL
.	NULL

Buffers	NULL
and	NULL
Solutions	NULL
.	NULL

TEG	NULL
buffer	NULL
consisted	NULL
of	NULL
25	NULL
mm	NULL
3-	NULL
[	NULL
tris	NULL
(	NULL
hydroxymethyl	NULL
)	NULL
methyiJaminopropane	NULL
sulfonic	NULL
acid	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
pH	NULL
8.2	NULL
.	NULL

SDS	NULL
sample	NULL
buffer	NULL
consisted	NULL
of	NULL
2	NULL
%	NULL
SDS	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
2	NULL
%	NULL
dithiothreitol	NULL
,	NULL
and	NULL
0.6	NULL
m	NULL
Tris	NULL
(	NULL
pH	NULL
8.85	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
Cells	NULL
.	NULL

Five	NULL
male	NULL
Sprague-Dawley	NULL
adrenalectomized	NULL
rats	NULL
were	NULL
sacrificed	NULL
by	NULL
decapitation	NULL
,	NULL
and	NULL
thymus	NULL
glands	NULL
were	NULL
removed	NULL
.	NULL

The	NULL
glands	NULL
were	NULL
minced	NULL
in	NULL
10	NULL
mi	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
separated	NULL
with	NULL
one	NULL
stroke	NULL
of	NULL
a	NULL
Corning	NULL
glass	NULL
tissue	NULL
homogenizer	NULL
.	NULL

The	NULL
cell	NULL
suspension	NULL
was	NULL
filtered	NULL
through	NULL
fine	NULL
nylon	NULL
mesh	NULL
and	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
cell	NULL
pellets	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
.	NULL

At	NULL
least	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
viable	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Cells	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Minnesota	NULL
and	NULL
received	NULL
at	NULL
ambient	NULL
temperature	NULL
within	NULL
24	NULL
hr	NULL
at	NULL
the	NULL
NIH	NULL
in	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

Peripheral	NULL
blood	NULL
was	NULL
diluted	NULL
at	NULL
least	NULL
1:5	NULL
in	NULL
Roswell	NULL
Park	NULL
Memoria	NULL
!	NULL

Institute	NULL
Tissue	NULL
Culture	NULL
Medium	NULL
1640	NULL
with	NULL
penicillin	NULL
(	NULL
50	NULL
ug/mi	NULL
)	NULL
,	NULL
genta-micin	NULL
(	NULL
50	NULL
glutamine	NULL
(	NULL
300	NULL
ug/ml	NULL
)	NULL
,	NULL
25	NULL
mm	NULL
4-	NULL
(	NULL
2	NULL
hydroxyethyl	NULL
)	NULL
1-piperazineethanesulfonic	NULL
acid	NULL
,	NULL
and	NULL
heparin	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
prior	NULL
to	NULL
ship-ment	NULL
.	NULL

The	NULL
mononuclear	NULL
white	NULL
cells	NULL
were	NULL
obtained	NULL
by	NULL
Ficoll	NULL
:	NULL
Hypaque	NULL
differential	NULL
centrifugation	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Boyum	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
95	NULL
%	NULL
viable	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Single-cell	NULL
suspensions	NULL
from	NULL
neoplastic	NULL
lymphoid	NULL
tissue	NULL
were	NULL
prepared	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Minnesota	NULL
.	NULL

If	NULL
the	NULL
single-cell	NULL
suspension	NULL
contained	NULL
at	NULL
least	NULL
50	NULL
%	NULL
malignant	NULL
cells	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
shipped	NULL
to	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

,	NULL
in	NULL
Roswell	NULL
Park	NULL
Memorial	NULL
Institute	NULL
Tissue	NULL
Culture	NULL
Medium	NULL
1640	NULL
.	NULL

The	NULL
preparations	NULL
were	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
.	NULL

Lymph	NULL
node	NULL
preparations	NULL
were	NULL
at	NULL
least	NULL
80	NULL
%	NULL
viable	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

°	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
HTC	NULL
,	NULL
hepatoma	NULL
tissue	NULL
culture	NULL
;	NULL
DM	NULL
,	NULL
dexametha-sone-21-mesylate	NULL
;	NULL
TA	NULL
,	NULL
triamcinolone	NULL
acetonide	NULL
;	NULL
TEG	NULL
,	NULL
3-	NULL
{	NULL
tris	NULL
(	NULL
hydroxymethyl	NULL
)	NULL
meth-yllaminopropane	NULL
sulfonic	NULL
acid	NULL
:	NULL
EDTA	NULL
:	NULL
glycerol	NULL
;	NULL
SDS	NULL
,	NULL
sodium	NULL
dodecyt	NULL
sulfate	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
ge	NULL
!	NULL

electrophoresis	NULL
.	NULL

5273	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

C.	NULL
M.	NULL
Foster	NULL
et	NULL
al	NULL
.	NULL

Preparation	NULL
of	NULL
Cytosolic	NULL
Fractions	NULL
.	NULL

Cell	NULL
suspensions	NULL
were	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
;	NULL
cell	NULL
peliets	NULL
were	NULL
frozen	NULL
at	NULL
-70°	NULL
and	NULL
then	NULL
thawed	NULL
at	NULL
4°	NULL
in	NULL
2.5	NULL
volumes	NULL
of	NULL
TEG	NULL
buffer	NULL
containing	NULL
50	NULL
mm	NULL
NaCI	NULL
.	NULL

When	NULL
completely	NULL
thawed	NULL
,	NULL
the	NULL
pellet	NULL
was	NULL
suspended	NULL
(	NULL
vortexed	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
(	NULL
cytosolic	NULL
)	NULL
fraction	NULL
was	NULL
collected	NULL
.	NULL

Labeling	NULL
of	NULL
Intact	NULL
Lymphoid	NULL
Cells	NULL
with	NULL
[	NULL
PHJDM	NULL
.	NULL

After	NULL
initial	NULL
preparation	NULL
of	NULL
cells	NULL
,	NULL
the	NULL
cell	NULL
peliets	NULL
were	NULL
suspended	NULL
in	NULL
10	NULL
volumes	NULL
of	NULL
PBS	NULL
.	NULL

Additions	NULL
were	NULL
made	NULL
(	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
text	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cell	NULL
suspensions	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cell	NULL
suspensions	NULL
were	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
;	NULL
supernatant	NULL
media	NULL
were	NULL
aspirated	NULL
,	NULL
and	NULL
the	NULL
cell	NULL
pellets	NULL
were	NULL
frozen	NULL
at	NULL
-70°	NULL
.	NULL

The	NULL
frozen	NULL
cell	NULL
pellets	NULL
were	NULL
thawed	NULL
at	NULL
4°	NULL
in	NULL
2.5	NULL
volumes	NULL
of	NULL
TEG	NULL
buffer	NULL
containing	NULL
20	NULL
mm	NULL
sodium	NULL
molybdate	NULL
and	NULL
then	NULL
centrifuged	NULL
in	NULL
an	NULL
Eppendorf	NULL
microcentrifuge	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Supernatant	NULL
fractions	NULL
(	NULL
140	NULL
ul	NULL
)	NULL
were	NULL
treated	NULL
immediately	NULL
with	NULL
SDS	NULL
sample	NULL
buffer	NULL
(	NULL
60	NULL
L	NULL
!	NULL
)	NULL

.	NULL

PAGE	NULL
.	NULL

Polyacrylamide	NULL
gels	NULL
(	NULL
9	NULL
%	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
%	NULL
SDS	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Laemmli	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Each	NULL
sample	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
was	NULL
heated	NULL
at	NULL
100°	NULL
for	NULL
1	NULL
min	NULL
before	NULL
applying	NULL
an	NULL
aliquot	NULL
(	NULL
40	NULL
ul	NULL
)	NULL
to	NULL
the	NULL
gel	NULL
.	NULL

A	NULL
Bio-Rad	NULL
slab	NULL
gel	NULL
apparatus	NULL
was	NULL
used	NULL
,	NULL
and	NULL
electrophoresis	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
100	NULL
V/slab	NULL
.	NULL

Gels	NULL
were	NULL
fixed	NULL
and	NULL
stained	NULL
in	NULL
50	NULL
%	NULL
methanol	NULL
,	NULL
7.5	NULL
%	NULL
acetic	NULL
acid	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
Coomassie	NULL
Brilliant	NULL
Blue	NULL
R250	NULL
and	NULL
destained	NULL
in	NULL
10	NULL
%	NULL
methanol	NULL
and	NULL
7.5	NULL
%	NULL
acetic	NULL
acid	NULL
.	NULL

Gel	NULL
lanes	NULL
were	NULL
cut	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
and	NULL
dissolved	NULL
in	NULL
0.6	NULL
ml	NULL
of	NULL
30	NULL
%	NULL
hydrogen	NULL
peroxide	NULL
at	NULL
40°	NULL
.	NULL

Radioactivity	NULL
was	NULL
determined	NULL
with	NULL
Ready-Solv	NULL
MP	NULL
and	NULL
a	NULL
Tracor	NULL
Mark	NULL
III	NULL
spectrometer	NULL
(	NULL
counting	NULL
efficiency	NULL
,	NULL
40	NULL
to	NULL
50	NULL
%	NULL
)	NULL
.	NULL

RESULTS	NULL
Affinity	NULL
Labeling	NULL
of	NULL
Rat	NULL
Thymocyte	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Cytosolic	NULL
Preparations	NULL
.	NULL

DM	NULL
has	NULL
been	NULL
used	NULL
previously	NULL
to	NULL
label	NULL
covalently	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
HTC	NULL
cell	NULL
cytosol	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
and	NULL
in	NULL
rat	NULL
liver	NULL
cytosol	NULL
(	NULL
7	NULL
)	NULL
,	NULL
presumably	NULL
through	NULL
reaction	NULL
with	NULL
thiol	NULL
anions	NULL
of	NULL
cysteine	NULL
residues	NULL
present	NULL
in	NULL
the	NULL
steroid	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Although	NULL
[	NULL
°H	NULL
]	NULL
DM	NULL
reacts	NULL
covalently	NULL
with	NULL
many	NULL
proteins	NULL
in	NULL
crude	NULL
cytosol	NULL
,	NULL
covalent	NULL
binding	NULL
between	NULL
[	NULL
°HJDM	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
can	NULL
be	NULL
inhibited	NULL
selectivity	NULL
by	NULL
unlabeled	NULL
glucocorticoid	NULL
,	NULL
such	NULL
as	NULL
TA	NULL
or	NULL
dexamethasone	NULL
(	NULL
19	NULL
)	NULL
.	NULL

[	NULL
°HJDM	NULL
binding	NULL
to	NULL
other	NULL
cytosolic	NULL
proteins	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
albumin	NULL
)	NULL
is	NULL
not	NULL
inhibited	NULL
competitively	NULL
by	NULL
excess	NULL
glucocorticoid	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Previous	NULL
work	NULL
with	NULL
rat	NULL
liver	NULL
has	NULL
shown	NULL
that	NULL
small-molecular-weight	NULL
compounds	NULL
present	NULL
in	NULL
crude	NULL
cytosol	NULL
prevent	NULL
[	NULL
°HJDM	NULL
binding	NULL
to	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
7	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
DM	NULL
labels	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
rat	NULL
thymocytes	NULL
,	NULL
crude	NULL
cytosol	NULL
was	NULL
incubated	NULL
with	NULL
25	NULL
nm	NULL
[	NULL
°HJTA	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
DM	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
.	NULL

DM	NULL
(	NULL
200	NULL
nm	NULL
)	NULL
inhibited	NULL
effectively	NULL
[	NULL
PH	NULL
]	NULL
JTA	NULL
binding	NULL
to	NULL
the	NULL
receptor	NULL
.	NULL

If	NULL
thymocyte	NULL
preparations	NULL
were	NULL
contaminated	NULL
with	NULL
RBCs	NULL
(	NULL
known	NULL
to	NULL
contain	NULL
high	NULL
levels	NULL
of	NULL
gluta-thione	NULL
)	NULL
,	NULL
such	NULL
competition	NULL
was	NULL
not	NULL
observed	NULL
.	NULL

In	NULL
such	NULL
prepara-tions	NULL
,	NULL
gel	NULL
filtration	NULL
could	NULL
be	NULL
used	NULL
to	NULL
remove	NULL
low-molecular-weight	NULL
moieties	NULL
that	NULL
interfered	NULL
with	NULL
receptor	NULL
labeling	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cytosolic	NULL
fractions	NULL
were	NULL
treated	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
TA	NULL
,	NULL
for	NULL
2	NULL
hr	NULL
at	NULL
4°	NULL
and	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
(	NULL
Chart	NULL
2	NULL
)	NULL
.	NULL

Several	NULL
°H-labeted	NULL
proteins	NULL
were	NULL
detected	NULL
in	NULL
sliced	NULL
gels	NULL
,	NULL
but	NULL
labeling	NULL
of	NULL
only	NULL
one	NULL
major	NULL
protein	NULL
band	NULL
(	NULL
M	NULL
,	NULL
=95,000	NULL
)	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
TA	NULL
.	NULL

Smaller	NULL
proteins	NULL
,	NULL
also	NULL
inhibited	NULL
by	NULL
excess	NULL
unlabeled	NULL
TA	NULL
,	NULL
were	NULL
not	NULL
detected	NULL
when	NULL
other	NULL
techniques	NULL
were	NULL
used	NULL
to	NULL
label	NULL
rat	NULL
thymocytes	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
saturability	NULL
of	NULL
the	NULL
M	NULL
,	NULL
295,000	NULL
moiety	NULL
provides	NULL
evidence	NULL
that	NULL
this	NULL
protein	NULL
is	NULL
the	NULL
specific	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
rat	NULL
thymocyte	NULL
cytosol	NULL
.	NULL

The	NULL
[	NULL
°HJDM-labeled	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
both	NULL
rat	NULL
liver	NULL
and	NULL
HTC	NULL
cells	NULL
has	NULL
been	NULL
identified	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
undergo	NULL
5274	NULL
13H1	NULL
dpm	NULL
x	NULL
10	NULL
4	NULL
1	NULL
1	NULL
1	NULL
L_	NULL
L	NULL
200	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
DEXAMETHASONE	NULL
21-MESYLATE	NULL
(	NULL
nM	NULL
)	NULL
Chart	NULL
1	NULL
.	NULL

Competition	NULL
of	NULL
DM	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Thymocyte	NULL
cytosol	NULL
was	NULL
treated	NULL
for	NULL
2	NULL
hr	NULL
at	NULL
4°	NULL
with	NULL
25	NULL
nm	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
plus	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
DM	NULL
.	NULL

Macromolecular-bound	NULL
[	NULL
°HJTA	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
hydroxylapatite	NULL
adsorption	NULL
assay	NULL
.	NULL

Samples	NULL
(	NULL
100	NULL
41	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
wuth400ulofa50	NULL
%	NULL
slunyofhydroxylapaﬂteinTEGbufferoontanngSOmuNaCl	NULL
and	NULL
20	NULL
mm	NULL
sodium	NULL
molybdate	NULL
.	NULL

The	NULL
hydroxylapatite	NULL
was	NULL
washed	NULL
3	NULL
times	NULL
by	NULL
centrifugation	NULL
in	NULL
3	NULL
ml	NULL
of	NULL
buffer	NULL
,	NULL
and	NULL
radioactivity	NULL
bound	NULL
to	NULL
the	NULL
pellet	NULL
was	NULL
determined	NULL
.	NULL

~-	NULL
~~	NULL
,	NULL
radioactivity	NULL
of	NULL
cytosol	NULL
treated	NULL
with	NULL
25	NULL
nm	NULL
[	NULL
°HJTA	NULL
and	NULL
10	NULL
am	NULL
TA	NULL
.	NULL

BH	NULL
]	NULL
dpm	NULL
x	NULL
10-2	NULL
GEL	NULL
SLICE	NULL
Chart	NULL
2	NULL
.	NULL

[	NULL
°HJOM	NULL
labeling	NULL
of	NULL
rat	NULL
thymocyte	NULL
cytosolic	NULL
proteins	NULL
as	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

Rat	NULL
thymocyte	NULL
cytosol	NULL
was	NULL
treated	NULL
with	NULL
200	NULL
nu	NULL
[	NULL
°HJDM	NULL
or	NULL
with	NULL
200	NULL
nim	NULL
PH	NULL
]	NULL
JDM	NULL
+	NULL
20	NULL
um	NULL
TA	NULL
at	NULL
4°	NULL
for	NULL
2	NULL
hr	NULL
.	NULL

Samples	NULL
(	NULL
100	NULL
L1	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
100	NULL
al	NULL
of	NULL
SDS	NULL
sample	NULL
buffer	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
gel	NULL
lanes	NULL
contain	NULL
the	NULL
proteins	NULL
from	NULL
40	NULL
ai	NULL
of	NULL
sample	NULL
.	NULL

@	NULL
,	NULL
[	NULL
°HJDM	NULL
;	NULL
O	NULL
,	NULL
[	NULL
°HJDM	NULL
+	NULL
TA	NULL
.	NULL

Molecular	NULL
weight	NULL
standards	NULL
:	NULL
P	NULL
,	NULL
b	NULL
(	NULL
M	NULL
,	NULL
&	NULL
97,000	NULL
)	NULL
;	NULL
A	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
M	NULL
,	NULL
&	NULL
67,000	NULL
)	NULL
;	NULL
OA	NULL
,	NULL
ovalbumin	NULL
(	NULL
M	NULL
,	NULL
«	NULL
45,000	NULL
)	NULL
;	NULL
CA	NULL
,	NULL
carbonic	NULL
anhydrase	NULL
(	NULL
M	NULL
,	NULL
=	NULL
31,000	NULL
)	NULL
.	NULL

temperature-dependent	NULL
``	NULL
activation	NULL
``	NULL
to	NULL
forms	NULL
that	NULL
bind	NULL
to	NULL
DNA-cellulose	NULL
(	NULL
12	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Rat	NULL
thymocyte	NULL
glucocorticoid	NULL
receptor	NULL
was	NULL
identified	NULL
similarly	NULL
by	NULL
warming	NULL
[	NULL
°H	NULL
]	NULL
JDM-labeled	NULL
cytosol	NULL
(	NULL
20°	NULL
for	NULL
30	NULL
min	NULL
)	NULL
and	NULL
then	NULL
cooling	NULL
to	NULL
4°	NULL
,	NULL
followed	NULL
by	NULL
chromatographing	NULL
on	NULL
DNA-cellulose	NULL
.	NULL

The	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
was	NULL
adsorbed	NULL
to	NULL
DNA-cellulose	NULL
and	NULL
could	NULL
be	NULL
eluted	NULL
by	NULL
buffer	NULL
containing	NULL
0.5	NULL
m	NULL
NaCI	NULL
(	NULL
Chart	NULL
3	NULL
)	NULL
.	NULL

Similar	NULL
chromatography	NULL
with	NULL
unheated	NULL
cytosol	NULL
showed	NULL
virtually	NULL
no	NULL
adsorption	NULL
of	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Affinity	NULL
Labeling	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
in	NULL
Intact	NULL
Thymocytes	NULL
.	NULL

Human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptors	NULL
appear	NULL
to	NULL
be	NULL
unstable	NULL
in	NULL
cell	NULL
extracts	NULL
(	NULL
6	NULL
)	NULL
and	NULL
therefore	NULL
should	NULL
be	NULL
labeled	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

We	NULL
used	NULL
rat	NULL
thymocytes	NULL
to	NULL
study	NULL
conditions	NULL
for	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

43	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

OA	NULL
CA	NULL
Ppo_	NULL
A	NULL
|	NULL
|	NULL
[	NULL
BH	NULL
]	NULL
dpm	NULL
x	NULL
10-3	NULL
bre	NULL
``	NULL
v	NULL
p	NULL
ao	NULL
40	NULL
_	NULL
50	NULL
60	NULL
70	NULL
GEL	NULL
SLICE	NULL
Chart	NULL
3	NULL
.	NULL

Binding	NULL
of	NULL
covalently	NULL
labeled	NULL
rat	NULL
thymocyte	NULL
glucocorticoid	NULL
receptor	NULL
to	NULL
DNA-cellulose	NULL
.	NULL

Rat	NULL
thymocyte	NULL
cytosol	NULL
was	NULL
treated	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJODM	NULL
+	NULL
20	NULL
um	NULL
TA	NULL
at	NULL
4°	NULL
for	NULL
2	NULL
hr	NULL
.	NULL

Aliquots	NULL
were	NULL
heated	NULL
at	NULL
20°	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
cooled	NULL
at	NULL
4°	NULL
.	NULL

A	NULL
1-mi	NULL
sample	NULL
was	NULL
applied	NULL
to	NULL
a	NULL
DNA-cellulose	NULL
column	NULL
(	NULL
bed	NULL
volume	NULL
=	NULL
2	NULL
mi	NULL
)	NULL
which	NULL
was	NULL
then	NULL
washed	NULL
with	NULL
20	NULL
ml	NULL
of	NULL
TEG	NULL
buffer	NULL
containing	NULL
0.05	NULL
m	NULL
NaC	NULL
;	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
column	NULL
were	NULL
eluted	NULL
by	NULL
8	NULL
m	NULL
!	NULL

of	NULL
TEG	NULL
buffer	NULL
containing	NULL
0.50	NULL
m	NULL
NaCl	NULL
.	NULL

Peak	NULL
fractions	NULL
(	NULL
1	NULL
mi	NULL
)	NULL
from	NULL
the	NULL
0.05	NULL
m	NULL
NaC	NULL
!	NULL

wash	NULL
and	NULL
0.50	NULL
m	NULL
NaCi	NULL
eluate	NULL
were	NULL
treated	NULL
with	NULL
100	NULL
«	NULL
l	NULL
of	NULL
100	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
trichloroacetic	NULL
acid	NULL
and	NULL
100	NULL
ug	NULL
of	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
(	NULL
as	NULL
carrier	NULL
)	NULL
for	NULL
2	NULL
hr	NULL
at	NULL
4°	NULL
.	NULL

Precipitates	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
dissolved	NULL
in	NULL
5	NULL
«	NULL
l	NULL
of	NULL
1	NULL
m	NULL
NaOH	NULL
;	NULL
100	NULL
ul	NULL
of	NULL
SDS	NULL
sample	NULL
buffer	NULL
were	NULL
added	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

®	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
JDM	NULL
;	NULL
O	NULL
,	NULL
[	NULL
°HJDM	NULL
+	NULL
TA	NULL
.	NULL

(	NULL
Abbreviations	NULL
for	NULL
standards	NULL
are	NULL
as	NULL
in	NULL
Chart	NULL
2	NULL
.	NULL
)	NULL

Sreng	NULL
\pape®	NULL
``	NULL
tet	NULL
90	NULL
)	NULL
.	NULL

PP	NULL
P	NULL
wel	NULL
10	NULL
20	NULL
-	NULL
30	NULL
80	NULL
_	NULL
90	NULL
BH	NULL
]	NULL
dpm	NULL
x	NULL
10-3	NULL
GEL	NULL
SLICE	NULL
Chart	NULL
4	NULL
.	NULL

[	NULL
°HJDM	NULL
labeling	NULL
of	NULL
intact	NULL
rat	NULL
thymocytes	NULL
as	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

Intact	NULL
rat	NULL
thymocytes	NULL
in	NULL
a	NULL
suspension	NULL
of	NULL
10	NULL
%	NULL
by	NULL
cytocrit	NULL
were	NULL
treated	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
alone	NULL
or	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
and	NULL
20	NULL
um	NULL
TA	NULL
for	NULL
2	NULL
hr	NULL
at	NULL
4°	NULL
.	NULL

Cytosol	NULL
(	NULL
140	NULL
ul	NULL
)	NULL
was	NULL
treated	NULL
with	NULL
60	NULL
4	NULL
!	NULL

of	NULL
sample	NULL
buffer	NULL
.	NULL

The	NULL
gel	NULL
lanes	NULL
contain	NULL
the	NULL
proteins	NULL
from	NULL
40	NULL
wi	NULL
of	NULL
sample	NULL
.	NULL

®	NULL
,	NULL
PHJOM	NULL
;	NULL
O	NULL
,	NULL
PHJDM	NULL
+	NULL
TA	NULL
.	NULL

(	NULL
Abbreviations	NULL
for	NULL
standards	NULL
are	NULL
as	NULL
in	NULL
Chart	NULL
2	NULL
.	NULL
)	NULL

affinity	NULL
labeling	NULL
in	NULL
intact	NULL
lymphoid	NULL
cells	NULL
.	NULL

Thymocytes	NULL
were	NULL
treated	NULL
at	NULL
4°	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
TA	NULL
.	NULL

At	NULL
4°	NULL
,	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
steroid	NULL
:	NULL
receptor	NULL
complex	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
minimal	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Cytosolic	NULL
fractions	NULL
were	NULL
prepared	NULL
and	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
(	NULL
Chart	NULL
4	NULL
)	NULL
.	NULL

There	NULL
was	NULL
less	NULL
nonspecific	NULL
protein	NULL
labeling	NULL
than	NULL
found	NULL
in	NULL
crude	NULL
cytosol	NULL
.	NULL

Further	NULL
,	NULL
specific	NULL
[	NULL
°HJDM	NULL
labeling	NULL
was	NULL
virtually	NULL
confined	NULL
to	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
concentration	NULL
of	NULL
[	NULL
°HJDM	NULL
and	NULL
of	NULL
time	NULL
of	NULL
treatment	NULL
on	NULL
receptor	NULL
binding	NULL
were	NULL
assessed	NULL
(	NULL
Chart	NULL
5	NULL
)	NULL
.	NULL

Receptor	NULL
labeling	NULL
was	NULL
detectable	NULL
at	NULL
10	NULL
min	NULL
and	NULL
was	NULL
maximal	NULL
after	NULL
30	NULL
min	NULL
;	NULL
100	NULL
nm	NULL
[	NULL
°HJDM	NULL
was	NULL
sufficient	NULL
to	NULL
label	NULL
the	NULL
receptor	NULL
maximally	NULL
.	NULL

The	NULL
labeling	NULL
efficiency	NULL
of	NULL
[	NULL
°HJDM	NULL
was	NULL
determined	NULL
by	NULL
labeling	NULL
rat	NULL
thy	NULL
NOVEMBER	NULL
1983	NULL
Rat	NULL
and	NULL
Human	NULL
Lymphoid	NULL
Glucocorticoid	NULL
Receptors	NULL
mocyte	NULL
suspensions	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
4°	NULL
with	NULL
100	NULL
nm	NULL
[	NULL
°HJDM	NULL
or	NULL
50	NULL
nm	NULL
[	NULL
PH	NULL
]	NULL
TA	NULL
+	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
TA	NULL
.	NULL

Specific	NULL
labeling	NULL
determined	NULL
directly	NULL
from	NULL
[	NULL
°H	NULL
]	NULL
TA-treated	NULL
cytosol	NULL
was	NULL
14,800	NULL
+	NULL
300	NULL
dpm	NULL
.	NULL

Specific	NULL
labeling	NULL
from	NULL
SDS	NULL
:	NULL
PAGE-analyzed	NULL
[	NULL
°HJDM-treated	NULL
cytosol	NULL
was	NULL
5,300	NULL
+	NULL
500	NULL
cpm	NULL
.	NULL

Therefore	NULL
,	NULL
[	NULL
°HJDM	NULL
labeling	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
was	NULL
35	NULL
%	NULL
of	NULL
that	NULL
found	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
.	NULL

Affinity	NULL
Labeling	NULL
of	NULL
the	NULL
Glucocorticoid	NULL
Receptor	NULL
in	NULL
Human	NULL
Leukemic	NULL
and	NULL
Lymphoma	NULL
Cells	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
from	NULL
neoplastic	NULL
cells	NULL
were	NULL
labeled	NULL
covalently	NULL
with	NULL
[	NULL
°HJDM	NULL
in	NULL
5	NULL
patient	NULL
samples	NULL
.	NULL

Patient	NULL
diagnosis	NULL
,	NULL
specimen	NULL
type	NULL
,	NULL
and	NULL
labeling	NULL
conditions	NULL
are	NULL
indicated	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

All	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
(	NULL
Chart	NULL
6	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
saturable	NULL
labeling	NULL
was	NULL
shown	NULL
for	NULL
a	NULL
M	NULL
,	NULL
=	NULL
95,000	NULL
protein	NULL
moiety	NULL
.	NULL

Saturable	NULL
labeling	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
a	NULL
M	NULL
,	NULL
=	NULL
45,000	NULL
protein	NULL
moiety	NULL
in	NULL
Patient	NULL
A	NULL
;	NULL
M	NULL
,	NULL
=	NULL
53,000	NULL
and	NULL
M	NULL
,	NULL
=	NULL
35,000	NULL
in	NULL
Patient	NULL
B	NULL
;	NULL
M	NULL
,	NULL
=	NULL
75,000	NULL
,	NULL
M	NULL
,	NULL
=	NULL
57,000	NULL
,	NULL
M	NULL
,	NULL
=	NULL
45,000	NULL
,	NULL
and	NULL
M	NULL
,	NULL
=	NULL
31,000	NULL
in	NULL
Patient	NULL
D	NULL
;	NULL
and	NULL
M	NULL
,	NULL
=	NULL
75,000	NULL
in	NULL
Patient	NULL
E.	NULL
No	NULL
additional	NULL
saturable	NULL
protein	NULL
moieties	NULL
were	NULL
seen	NULL
in	NULL
Patient	NULL
C.	NULL
DISCUSSION	NULL
This	NULL
study	NULL
represents	NULL
the	NULL
first	NULL
application	NULL
of	NULL
affinity	NULL
labeling	NULL
to	NULL
the	NULL
analysis	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
human	NULL
leukemia	NULL
and	NULL
malignant	NULL
lymphoma	NULL
.	NULL

When	NULL
malignant	NULL
cells	NULL
obtained	NULL
from	NULL
lymph	NULL
node	NULL
biopsy	NULL
or	NULL
from	NULL
peripheral	NULL
blood	NULL
are	NULL
treated	NULL
with	NULL
[	NULL
°HJDM	NULL
,	NULL
labeled	NULL
receptor	NULL
can	NULL
be	NULL
analyzed	NULL
under	NULL
denaturing	NULL
conditions	NULL
.	NULL

In	NULL
the	NULL
5	NULL
cases	NULL
studied	NULL
,	NULL
an	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
showed	NULL
that	NULL
specific	NULL
binding	NULL
of	NULL
[	NULL
°HJDM	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
found	NULL
for	NULL
the	NULL
rat	NULL
T	NULL
T	NULL
T	NULL
T	NULL
B	NULL
I	NULL
T	NULL
A	NULL
at	NULL
.	NULL

|	NULL
4	NULL
*	NULL
{	NULL
--	NULL
*	NULL
10	NULL
3	NULL
BHI	NULL
dpm	NULL
x	NULL
n	NULL
i_	NULL
[	NULL
BH	NULL
]	NULL
dpm	NULL
x	NULL
103	NULL
1	NULL
i	NULL
1	NULL
il	NULL
1	NULL
1	NULL
1	NULL
30	NULL
60	NULL
90	NULL
120	NULL
100	NULL
_	NULL
200	NULL
1000	NULL
MINUTES	NULL
[	NULL
3H	NULL
]	NULL
DEXAMETHASONE	NULL
21-MESYLATE	NULL
(	NULL
nM	NULL
}	NULL
Chart	NULL
5	NULL
.	NULL

Experimental	NULL
conditions	NULL
affecting	NULL
affinity	NULL
labeling	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

In	NULL
A	NULL
,	NULL
cell	NULL
suspensions	NULL
(	NULL
10	NULL
%	NULL
by	NULL
cytocrit	NULL
)	NULL
were	NULL
labeled	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

Reactions	NULL
were	NULL
stopped	NULL
by	NULL
freezing	NULL
the	NULL
cell	NULL
pellets	NULL
.	NULL

Cytosol	NULL
(	NULL
140	NULL
a	NULL
!	NULL
)	NULL

was	NULL
treated	NULL
with	NULL
60	NULL
al	NULL
of	NULL
sample	NULL
buffer	NULL
,	NULL
and	NULL
40	NULL
al	NULL
of	NULL
sample	NULL
were	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

Radioactivity	NULL
in	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
peak	NULL
was	NULL
determined	NULL
.	NULL

In	NULL
B	NULL
,	NULL
cell	NULL
suspensions	NULL
(	NULL
10	NULL
%	NULL
by	NULL
cytocrit	NULL
)	NULL
were	NULL
labeled	NULL
for	NULL
1	NULL
hr	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
[	NULL
°HJOM	NULL
.	NULL

Reactions	NULL
were	NULL
stopped	NULL
by	NULL
freezing	NULL
the	NULL
call	NULL
pellets	NULL
.	NULL

Cytosols	NULL
(	NULL
140	NULL
L	NULL
!	NULL
)	NULL

were	NULL
treated	NULL
with	NULL
60	NULL
«	NULL
I	NULL
of	NULL
sample	NULL
buffer	NULL
,	NULL
and	NULL
40	NULL
ul	NULL
of	NULL
sample	NULL
were	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

Radioactivity	NULL
in	NULL
the	NULL
M	NULL
,	NULL
«	NULL
95,000	NULL
peak	NULL
was	NULL
determined	NULL
.	NULL

Points	NULL
,	NULL
average	NULL
of	NULL
2	NULL
determinations	NULL
.	NULL

Table	NULL
1	NULL
Patient	NULL
data	NULL
and	NULL
labeling	NULL
conditions	NULL
Pre-	NULL
Con	NULL
vious	NULL
centra-	NULL
steroid	NULL
tion	NULL
of	NULL
Diagno-	NULL
_	NULL
Patient	NULL
_	NULL
treat-	NULL
Source	NULL
of	NULL
Labeling	NULL
_	NULL
[	NULL
°HJDOM	NULL
Patient	NULL
sis	NULL
status	NULL
ment	NULL
sample	NULL
conditions	NULL
{	NULL
nm	NULL
)	NULL
A	NULL
ALL	NULL
New	NULL
No	NULL
Blood	NULL
Cytosol	NULL
200	NULL
B	NULL
ALL	NULL
New	NULL
No	NULL
Blood	NULL
Intact	NULL
cells	NULL
200	NULL
C	NULL
N-PDLL	NULL
_	NULL
Relapse	NULL
Yes	NULL
Lymph	NULL
node	NULL
_	NULL
Intact	NULL
cells	NULL
100	NULL
D	NULL
WDLL	NULL
New	NULL
No	NULL
Lymph	NULL
node	NULL
_	NULL
Intact	NULL
cells	NULL
100	NULL
E	NULL
N-PDLL	NULL
_	NULL
Relapse	NULL
Yes	NULL
Lymph	NULL
node	NULL
_	NULL
intact	NULL
cells	NULL
100	NULL
``	NULL
ALL	NULL
,	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
;	NULL
N-PDLL	NULL
,	NULL
nodular	NULL
poorly	NULL
differentiated	NULL
lymphocytic	NULL
lymphoma	NULL
;	NULL
WDLL	NULL
,	NULL
well-differentiated	NULL
lymphocytic	NULL
lymphoma	NULL
.	NULL

5275	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

C.	NULL
M.	NULL
Foster	NULL
et	NULL
al	NULL
.	NULL

T	NULL
T	NULL
T	NULL
T	NULL
4-1	NULL
<	NULL
--	NULL
>	NULL
<	NULL
-	NULL
LH	NULL
}	NULL
dpm	NULL
»	NULL
x	NULL
10°2	NULL
(	NULL
``	NULL
H	NULL
}	NULL
domx	NULL
102	NULL
t	NULL
&	NULL
8	NULL
}	NULL
[	NULL
PH	NULL
]	NULL
dpm	NULL
x	NULL
10	NULL
%	NULL
2	NULL
[	NULL
H	NULL
}	NULL
dpm	NULL
»	NULL
x	NULL
10°2	NULL
1	NULL
i	NULL
1	NULL
1	NULL
1	NULL
1	NULL
i	NULL
i	NULL
20	NULL
40	NULL
60	NULL
80	NULL
20	NULL
40	NULL
60	NULL
80	NULL
GEL	NULL
SLICE	NULL
GEL	NULL
SLICE	NULL
T	NULL
I	NULL
T	NULL
T	NULL
E	NULL
P	NULL
A	NULL
OA	NULL
CA	NULL
o	NULL
I	NULL
_L	NULL
[	NULL
PH	NULL
]	NULL
dpm	NULL
x	NULL
10~2	NULL
P3	NULL
GEL	NULL
SUCE	NULL
Chart	NULL
6	NULL
.	NULL

[	NULL
°HJDM	NULL
labeling	NULL
of	NULL
human	NULL
lymphoma	NULL
and	NULL
leukemic	NULL
cell	NULL
glucocorticoid	NULL
receptor	NULL
as	NULL
analyzed	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

Gel	NULL
lanes	NULL
contain	NULL
proteins	NULL
from	NULL
40	NULL
l	NULL
of	NULL
sample	NULL
.	NULL

(	NULL
Abbreviations	NULL
for	NULL
standards	NULL
are	NULL
as	NULL
in	NULL
Chart	NULL
2	NULL
.	NULL
)	NULL

In	NULL
A	NULL
,	NULL
cytosol	NULL
from	NULL
circulating	NULL
blasts	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
was	NULL
labeled	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
alone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
20	NULL
um	NULL
TA	NULL
(	NULL
0	NULL
)	NULL
.	NULL

One	NULL
hundred	NULL
«	NULL
l	NULL
of	NULL
cytosol	NULL
were	NULL
combined	NULL
with	NULL
100	NULL
L	NULL
!	NULL

of	NULL
sample	NULL
buffer	NULL
.	NULL

In	NULL
B	NULL
,	NULL
a	NULL
5	NULL
%	NULL
cell	NULL
suspension	NULL
by	NULL
cytocrit	NULL
of	NULL
circulating	NULL
blasts	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
was	NULL
labeled	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
alone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
20	NULL
um	NULL
TA	NULL
(	NULL
0	NULL
)	NULL
.	NULL

The	NULL
frozen	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
TEG	NULL
buffer	NULL
with	NULL
20	NULL
mm	NULL
sodium	NULL
molybdate	NULL
.	NULL

One	NULL
hundred	NULL
«	NULL
!	NULL

of	NULL
cytosol	NULL
were	NULL
combined	NULL
with	NULL
100	NULL
«	NULL
I	NULL
of	NULL
sample	NULL
buffer	NULL
.	NULL

In	NULL
C	NULL
,	NULL
intact	NULL
lymphoma	NULL
cells	NULL
ﬁanchphnMedambthnodﬂwpoMydﬁaMtedmeMcyﬁcMﬂmmhwedmm1wnM	NULL
[	NULL
°H10Ma|one	NULL
(	NULL
0	NULL
)	NULL
onncombmahonwm10mTA	NULL
(	NULL
O	NULL
)	NULL
Cytosol	NULL
was	NULL
prepared	NULL
as	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

In	NULL
D	NULL
,	NULL
intact	NULL
lymphoma	NULL
cells	NULL
from	NULL
a	NULL
lymph	NULL
node	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
diffuse	NULL
well-differentiated	NULL
lymphoma	NULL
were	NULL
labeled	NULL
with	NULL
100	NULL
nm	NULL
[	NULL
°HJDM	NULL
alone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
10	NULL
um	NULL
TA	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Cytosol	NULL
was	NULL
prepared	NULL
as	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

In	NULL
E	NULL
,	NULL
intact	NULL
malignant	NULL
cells	NULL
from	NULL
a	NULL
lymph	NULL
node	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
nodular	NULL
,	NULL
poodydvﬂemnmtedlymphocyﬁclymp'mlammeledwim100nu	NULL
[	NULL
‘	NULL
H	NULL
]	NULL
DMalone	NULL
(	NULL
.	NULL
)	NULL

0fncantmahonmmiouuTA	NULL
(	NULL
O	NULL
)	NULL
Cytosol	NULL
was	NULL
prepared	NULL
as	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

5276	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

43	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

thymocyte	NULL
.	NULL

Saturability	NULL
with	NULL
excess	NULL
unlabeled	NULL
steroid	NULL
(	NULL
such	NULL
as	NULL
TA	NULL
)	NULL
and	NULL
ability	NULL
to	NULL
undergo	NULL
activation	NULL
and	NULL
bind	NULL
to	NULL
DNA-celluiose	NULL
(	NULL
properties	NULL
of	NULL
noncovalently	NULL
radiolabeled	NULL
lymphoid	NULL
glucocorticoid	NULL
receptor	NULL
)	NULL
are	NULL
retained	NULL
by	NULL
rat	NULL
thymocyte	NULL
receptor	NULL
which	NULL
has	NULL
been	NULL
labeled	NULL
covalently	NULL
with	NULL
[	NULL
°HJDM	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
those	NULL
of	NULL
Simons	NULL
and	NULL
coworkers	NULL
(	NULL
7	NULL
,	NULL
19	NULL
)	NULL
and	NULL
Milgrom	NULL
(	NULL
12	NULL
)	NULL
,	NULL
who	NULL
have	NULL
demonstrated	NULL
similar	NULL
properties	NULL
in	NULL
rat	NULL
liver	NULL
cytosol	NULL
and	NULL
in	NULL
rat	NULL
HTC	NULL
cells	NULL
.	NULL

Rat	NULL
thymocyte	NULL
glucocorticoid	NULL
receptor	NULL
has	NULL
M	NULL
,	NULL
=	NULL
95,000	NULL
as	NULL
determined	NULL
by	NULL
SDS	NULL
:	NULL
PAGE	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
of	NULL
molecular	NULL
weight	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
rat	NULL
liver	NULL
and	NULL
in	NULL
rat	NULL
HTC	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
19	NULL
)	NULL
.	NULL

This	NULL
moiety	NULL
represents	NULL
the	NULL
reduced	NULL
denatured	NULL
fundamental	NULL
unit	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Under	NULL
nondenaturing	NULL
conditions	NULL
,	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
is	NULL
apparently	NULL
much	NULL
larger	NULL
and	NULL
may	NULL
consist	NULL
of	NULL
a	NULL
multimer	NULL
of	NULL
receptor	NULL
subunits	NULL
or	NULL
a	NULL
complex	NULL
with	NULL
other	NULL
nonreceptor	NULL
proteins	NULL
(	NULL
15	NULL
,	NULL
17	NULL
,	NULL
23	NULL
)	NULL
.	NULL

In	NULL
human	NULL
malignant	NULL
lymphoid	NULL
cells	NULL
,	NULL
an	NULL
M	NULL
,	NULL
295,000	NULL
moiety	NULL
is	NULL
labeled	NULL
covalently	NULL
with	NULL
[	NULL
°HJDM	NULL
,	NULL
and	NULL
labeling	NULL
is	NULL
inhibited	NULL
by	NULL
excess	NULL
TA	NULL
.	NULL

The	NULL
limited	NULL
quantities	NULL
of	NULL
patient	NULL
material	NULL
have	NULL
not	NULL
permitted	NULL
analysis	NULL
of	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
moiety	NULL
by	NULL
activation	NULL
and	NULL
binding	NULL
to	NULL
DNA-cellulose	NULL
.	NULL

Four	NULL
of	NULL
the	NULL
5	NULL
human	NULL
neoplastic	NULL
cell	NULL
samples	NULL
show	NULL
saturable	NULL
bindings	NULL
of	NULL
smaller	NULL
labeled	NULL
moieties	NULL
(	NULL
M	NULL
,	NULL
=	NULL
75,000	NULL
,	NULL
M	NULL
,	NULL
=	NULL
57,000	NULL
,	NULL
M	NULL
,	NULL
=	NULL
45,000	NULL
,	NULL
M	NULL
,	NULL
=	NULL
35,000	NULL
,	NULL
and	NULL
M	NULL
,	NULL
=	NULL
31,000	NULL
)	NULL
.	NULL

These	NULL
moieties	NULL
may	NULL
represent	NULL
proteolytic	NULL
fragments	NULL
of	NULL
the	NULL
M	NULL
,	NULL
=95,000	NULL
receptor	NULL
subunit	NULL
.	NULL

The	NULL
glucocorticoid	NULL
receptor	NULL
is	NULL
unstable	NULL
in	NULL
some	NULL
human	NULL
leukemic	NULL
cell	NULL
extracts	NULL
(	NULL
6	NULL
)	NULL
and	NULL
may	NULL
be	NULL
subjected	NULL
to	NULL
proteolysis	NULL
during	NULL
the	NULL
limited	NULL
exposure	NULL
to	NULL
cell-free	NULL
conditions	NULL
in	NULL
our	NULL
present	NULL
assay	NULL
.	NULL

When	NULL
the	NULL
covalently	NULL
labeled	NULL
rat	NULL
liver	NULL
receptor	NULL
is	NULL
treated	NULL
with	NULL
exogenous	NULL
proteases	NULL
such	NULL
as	NULL
trypsin	NULL
,	NULL
multiple	NULL
smaller	NULL
labeled	NULL
forms	NULL
are	NULL
produced	NULL
.	NULL

*	NULL
Alterna-tively	NULL
,	NULL
these	NULL
smaller	NULL
moieties	NULL
may	NULL
be	NULL
present	NULL
in	NULL
the	NULL
intact	NULL
cell	NULL
and	NULL
could	NULL
be	NULL
produced	NULL
by	NULL
processes	NULL
that	NULL
do	NULL
not	NULL
involve	NULL
proteolysis	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
mRNA	NULL
processing	NULL
to	NULL
smaller	NULL
species	NULL
that	NULL
encode	NULL
only	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
M	NULL
,	NULL
=	NULL
95,000	NULL
subunit	NULL
)	NULL
.	NULL

Covalent	NULL
labeling	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
lymphoid	NULL
cells	NULL
may	NULL
be	NULL
performed	NULL
in	NULL
intact	NULL
cells	NULL
or	NULL
cell	NULL
extracts	NULL
.	NULL

However	NULL
,	NULL
fewer	NULL
proteins	NULL
are	NULL
nonsaturably	NULL
labeled	NULL
in	NULL
intact	NULL
thymocytes	NULL
than	NULL
in	NULL
cell	NULL
extracts	NULL
,	NULL
and	NULL
specifically	NULL
labeled	NULL
proteins	NULL
with	NULL
molecular	NULL
weight	NULL
less	NULL
than	NULL
=95,000	NULL
are	NULL
present	NULL
in	NULL
cell	NULL
extracts	NULL
which	NULL
are	NULL
not	NULL
present	NULL
when	NULL
intact	NULL
cells	NULL
are	NULL
labeled	NULL
(	NULL
Charts	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

These	NULL
initial	NULL
studies	NULL
demonstrate	NULL
that	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
intact	NULL
human	NULL
malignant	NULL
cells	NULL
can	NULL
be	NULL
labeled	NULL
covalently	NULL
.	NULL

The	NULL
methods	NULL
in	NULL
the	NULL
current	NULL
study	NULL
(	NULL
rapid	NULL
denaturing	NULL
of	NULL
cytosolic	NULL
proteins	NULL
with	NULL
SDS	NULL
)	NULL
appear	NULL
suitable	NULL
for	NULL
protection	NULL
of	NULL
thymocyte	NULL
and	NULL
some	NULL
human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptors	NULL
from	NULL
proteases	NULL
but	NULL
may	NULL
not	NULL
provide	NULL
sufficiently	NULL
rapid	NULL
denaturation	NULL
of	NULL
all	NULL
human	NULL
lymphoid	NULL
cells	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
evaluating	NULL
techniques	NULL
to	NULL
denature	NULL
cells	NULL
directly	NULL
in	NULL
an	NULL
effort	NULL
to	NULL
minimize	NULL
formation	NULL
of	NULL
smaller	NULL
labeled	NULL
proteins	NULL
.	NULL

Further	NULL
,	NULL
it	NULL
will	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
evaluate	NULL
cytosols	NULL
of	NULL
malignant	NULL
ceils	NULL
to	NULL
identify	NULL
factors	NULL
that	NULL
either	NULL
promote	NULL
or	NULL
protect	NULL
against	NULL
formation	NULL
of	NULL
receptor	NULL
fragments	NULL
.	NULL

*M.	NULL
E.	NULL
Reichman	NULL
,	NULL
C.	NULL
M.	NULL
Foster	NULL
,	NULL
S.	NULL
S.	NULL
Simons	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Eisen	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

NOVEMBER	NULL
1983	NULL
Rat	NULL
and	NULL
Human	NULL
Lymphoid	NULL
Glucocorticoid	NULL
Receptors	NULL
ACKNOWLEDGMENTS	NULL
We	NULL
would	NULL
like	NULL
to	NULL
thank	NULL
Linda	NULL
A.	NULL
Hamilton	NULL
for	NULL
her	NULL
expert	NULL
secretarial	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bell	NULL
,	NULL
R.	NULL
,	NULL
Lillquist	NULL
,	NULL
A.	NULL
,	NULL
Cotter	NULL
,	NULL
S.	NULL
,	NULL
Sailan	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
McCaffrey	NULL
,	NULL
R.	NULL
Mechanisms	NULL
of	NULL
glucocorticoid	NULL
resistance	NULL
in	NULL
lymphoblastic	NULL
malignancy	NULL
(	NULL
Abstract	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
58	NULL
(	NULL
Suppl	NULL
.	NULL

1	NULL
)	NULL
;	NULL
127	NULL
,	NULL
1981	NULL
.	NULL

2	NULL
.	NULL

Bloom	NULL
,	NULL
E.	NULL
,	NULL
Matulick	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Lan	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Higgins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
and	NULL
Baxter	NULL
,	NULL
J.	NULL
D.	NULL
Nuclear	NULL
binding	NULL
of	NULL
glucooorhcmd	NULL
receptors	NULL
:	NULL
relations	NULL
between	NULL
cytosol	NULL
binding	NULL
,	NULL
activation	NULL
,	NULL
and	NULL
the	NULL
biological	NULL
response	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
12	NULL
:	NULL
175-184	NULL
,	NULL
1980	NULL
.	NULL

3	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Zaleskas	NULL
,	NULL
J.	NULL
,	NULL
Frizzera	NULL
,	NULL
G.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hildebrandt	NULL
,	NULL
L.	NULL
,	NULL
Gall—Peczalska	NULL
K.	NULL
J.	NULL
,	NULL
and	NULL
Munck	NULL
A	NULL
.	NULL

In	NULL
vitro	NULL
gluoocomcoid	NULL
studies	NULL
for	NULL
predicting	NULL
responses	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
in	NULL
adults	NULL
with	NULL
malignant	NULL
lymphoma	NULL
.	NULL

Lancet	NULL
,	NULL
1	NULL
:	NULL
952-956	NULL
,	NULL
1980	NULL
.	NULL

4	NULL
.	NULL

Boyum	NULL
,	NULL
A	NULL
.	NULL

Isolation	NULL
of	NULL
mononuclear	NULL
cells	NULL
and	NULL
granulocytes	NULL
from	NULL
human	NULL
blood	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
21	NULL
(	NULL
Suppl	NULL
.	NULL

97	NULL
)	NULL
77-96	NULL
,	NULL
1968	NULL
.	NULL

§	NULL
.	NULL

Claman	NULL
,	NULL
H.	NULL
N.	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
287	NULL
:	NULL
388-397	NULL
,	NULL
1972	NULL
.	NULL

6	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
sensitivity	NULL
of	NULL
isolated	NULL
human	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4268-4272	NULL
,	NULL
1978	NULL
.	NULL

7	NULL
.	NULL

Eisen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Schleenbaker	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Simons	NULL
,	NULL
S.	NULL
S.	NULL
Affinity	NULL
labeling	NULL
of	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
with	NULL
dexamethasone-21-mesylate	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
256	NULL
;	NULL
12920-12925	NULL
,	NULL
1981	NULL
.	NULL

8	NULL
.	NULL

Goldin	NULL
,	NULL
A.	NULL
,	NULL
Sandberg	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Henderson	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
and	NULL
Newman	NULL
,	NULL
J.	NULL
W.	NULL
The	NULL
chemotherapy	NULL
of	NULL
human	NULL
and	NULL
animal	NULL
acute	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Chemother	NULL
.	NULL

Rep.	NULL
,	NULL
§5	NULL
:	NULL
309-507	NULL
,	NULL
1971	NULL
.	NULL

9	NULL
.	NULL

Laemmifi	NULL
,	NULL
U.	NULL
K.	NULL
Cleavage	NULL
of	NULL
structure	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T..	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
227	NULL
:	NULL
680-685	NULL
,	NULL
1970	NULL
.	NULL

10	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Halterman	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Levinthal	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
binding	NULL
proteins	NULL
in	NULL
human	NULL
acute	NULL
lymphoblastic	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
52	NULL
:	NULL
1715-1725	NULL
,	NULL
1973	NULL
.	NULL

11	NULL
.	NULL

McCaffrey	NULL
,	NULL
R.	NULL
,	NULL
Lillquist	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
R.	NULL
Abnormal	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
acute	NULL
leukemic	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
59	NULL
:	NULL
393-400	NULL
,	NULL
1982	NULL
.	NULL

12	NULL
.	NULL

Milgrom	NULL
,	NULL
E.	NULL
Activation	NULL
of	NULL
steroid	NULL
receptor	NULL
complexes	NULL
.	NULL

in	NULL
:	NULL
G.	NULL
Litwack	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Biochemical	NULL
Actions	NULL
of	NULL
Hormones	NULL
,	NULL
Vol	NULL
.	NULL

8	NULL
,	NULL
pp	NULL
.	NULL

465-492	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Academic	NULL
Press	NULL
,	NULL
Inc.	NULL
,	NULL
1981	NULL
.	NULL

13	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Lan	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Showers	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
and	NULL
Baxter	NULL
,	NULL
J.	NULL
D.	NULL
Photoaffinity	NULL
fabeling	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
256	NULL
:	NULL
10503-10508	NULL
,	NULL
1981	NULL
.	NULL

14	NULL
.	NULL

Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Harmon	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Activation	NULL
labile	NULL
glucocorticoid	NULL
receptor	NULL
complexes	NULL
of	NULL
a	NULL
steroid	NULL
resistant	NULL
variant	NULL
of	NULL
CEM-C7	NULL
human	NULL
lymphoid	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
286	NULL
:	NULL
507-510	NULL
,	NULL
1980	NULL
.	NULL

15	NULL
.	NULL

Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Litwack	NULL
,	NULL
G.	NULL
Activation	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
complex	NULL
.	NULL

Physiol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
62	NULL
:	NULL
1131-1192	NULL
,	NULL
1982	NULL
.	NULL

16	NULL
.	NULL

Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
receptor	NULL
function	NULL
in	NULL
leukemic	NULL
cells	NULL
.	NULL

in	NULL
:	NULL
R.	NULL
K.	NULL
Sharma	NULL
and	NULL
W.	NULL
E.	NULL
Criss	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Endocrine	NULL
Control	NULL
of	NULL
Neoplasia	NULL
,	NULL
Vol	NULL
.	NULL

1	NULL
,	NULL
pp	NULL
.	NULL

263-290	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1978	NULL
.	NULL

17	NULL
.	NULL

Sherman	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Pickering	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Rollwagen	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
and	NULL
Miller	NULL
,	NULL
L.	NULL
K.	NULL
Merore-ceptors	NULL
:	NULL
proteolytic	NULL
fragments	NULL
of	NULL
receptors	NULL
containing	NULL
the	NULL
steroid	NULL
binding	NULL
site	NULL
.	NULL

Fed	NULL
.	NULL

Proc	NULL
.	NULL

,	NULL
37	NULL
:	NULL
167-173	NULL
,	NULL
1978	NULL
.	NULL

18	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Pons	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
D.	NULL
F.	NULL
«	NULL
-Ketomesylate	NULL
:	NULL
a	NULL
reactive	NULL
thiol	NULL
specific	NULL
function	NULL
group	NULL
.	NULL

J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
45	NULL
:	NULL
3084-3088	NULL
,	NULL
1980	NULL
.	NULL

19	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Schieenbaker	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Eisen	NULL
,	NULL
H.	NULL
J.	NULL
Activation	NULL
of	NULL
covalent	NULL
affinity	NULL
labeled	NULL
glucocorticoid	NULL
receptor-steroid	NULL
complexes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
258	NULL
:	NULL
2229-2238	NULL
,	NULL
1983	NULL
.	NULL

20	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Dexamethasone-21-mesylate	NULL
:	NULL
an	NULL
affinity	NULL
label	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
from	NULL
rat	NULL
hepatoma	NULL
tissue	NULL
culture	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A.	NULL
,	NULL
78	NULL
:	NULL
3541-3545	NULL
,	NULL
1981	NULL
.	NULL

21	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Affinity	NULL
labeling	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
:	NULL
new	NULL
methods	NULL
.	NULL

in	NULL
:	NULL
G.	NULL
Litwack	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Biochemical	NULL
Actions	NULL
of	NULL
Hormones	NULL
,	NULL
Vol	NULL
.	NULL

9	NULL
,	NULL
pp	NULL
.	NULL

221-254	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Academic	NULL
Press	NULL
,	NULL
Inc.	NULL
,	NULL
1982	NULL
.	NULL

22	NULL
.	NULL

Stevens	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Stevens	NULL
,	NULL
Y.	NULL
W.	NULL
Physiochemical	NULL
differences	NULL
between	NULL
glucocorticoid	NULL
binding	NULL
components	NULL
from	NULL
the	NULL
corticoid-sensitive	NULL
and	NULL
-resistant	NULL
strains	NULL
of	NULL
mouse	NULL
lymphoma	NULL
P1798	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
39	NULL
:	NULL
4011-4021	NULL
,	NULL
1979	NULL
.	NULL

23	NULL
.	NULL

Vedeckis	NULL
,	NULL
W.	NULL
V.	NULL
Activation	NULL
and	NULL
chromatographic	NULL
properties	NULL
of	NULL
the	NULL
AtT-20	NULL
mouse	NULL
pituitary	NULL
tumor	NULL
cell	NULL
line	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Biochemistry	NULL
,	NULL
20	NULL
:	NULL
7237-7245	NULL
,	NULL
1981	NULL
.	NULL

5277	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Covalent	NULL
Labeling	NULL
of	NULL
Rat	NULL
Thymocyte	NULL
and	NULL
Human	NULL
Lymphoid	NULL
Glucocorticoid	NULL
Receptor	NULL
Carol	NULL
M.	NULL
Foster	NULL
,	NULL
Howard	NULL
J.	NULL
Eisen	NULL
and	NULL
Clara	NULL
D.	NULL
Bloomfield	NULL
Cancer	NULL
Res	NULL
1983	NULL
;	NULL
43:5273-5277	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/43/1	NULL
1/5273	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
1/5273	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1983	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

